Last updated: February 15, 2026
What is NDC 72603-0322?
NDC 72603-0322 refers to a specific drug product registered under the National Drug Code system. According to available data, this NDC corresponds to Benralizumab (Fasenra), a monoclonal antibody indicated for severe eosinophilic asthma.
Current Market Position
Benralizumab entered the U.S. market in 2017. It is marketed through AstraZeneca, competing primarily with other biologics in eosinophilic asthma such as Mepolizumab (Nucala), Reslizumab (Cinqair), and Dupilumab (Dupixent).
Market Size and Growth
The global asthma biologics market was valued at approximately $8.5 billion in 2022[1]. The U.S. accounts for about 50%, owing to high prevalence rates and early adoption.
The sector exhibits a compound annual growth rate (CAGR) of 8-10% from 2022 through 2030, driven by increased diagnosis, expanding indications, and broader payer coverage.
In particular, nasal eosinophilic and severe asthma, along with potential off-label uses like COPD, underpin market expansion.
Market Penetration and Revenue
In 2022, estimated U.S. sales of Benralizumab approached $1.7 billion, with some projections indicating a trajectory toward $2.2 billion by 2025[2].
Market share among biologics in severe asthma remains competitive:
| Biologic |
Approximate U.S. Market Share (2022) |
Notes |
| Mepolizumab |
40% |
Market leader in eosinophilic asthma |
| Benralizumab |
35% |
Rapid adoption since approval |
| Reslizumab |
12% |
Smaller, with specific patient subset |
| Dupilumab |
13% |
Growing, with broader indications |
Price and Reimbursement Dynamics
Benralizumab's list price averaged $33,000 per year during 2022. Variability exists based on payer contracts and discounts, with actual patient costs often lower due to rebates, copay assistance, and insurance negotiations.
Payer coverage is widespread, with most commercial, Medicare, and Medicaid plans covering the drug. The high cost pressures have led to increased emphasis on biosimilars or alternative therapies, although as of 2023, no biosimilar for Benralizumab has entered the market.
Price Projection for 2024-2028
Considering current market conditions and competitive pressures, pricing is expected to decline modestly:
| Year |
Estimated Price per Treatment Year |
Rationale |
| 2024 |
$31,000 |
Slight price erosion due to payer negotiations |
| 2025 |
$29,000 |
Increased competition influences patient access |
| 2026 |
$27,000 |
Anticipated emergence of biosimilars or generics |
| 2027 |
$25,000 |
Cost containment trends persist |
| 2028 |
$24,000 |
Market stabilization and generic availability |
Key Market Risks
- Patent Expirations and Biosimilar Entry: Although no biosimilars exist yet for Benralizumab, pending patent cliffs could pressure prices after 2028.
- Regulatory Approvals: Off-label approvals or expanded indications, such as COPD or atopic dermatitis, could alter market dynamics.
- Pricing & Reimbursement Policies: Legislative efforts to cap drug prices or enhance value-based pricing could impact revenue and pricing strategies.
Key Takeaways
- NDC 72603-0322 (Benralizumab) commands high market share within the severe asthma biologic segment.
- The U.S. market for eosinophilic asthma biologics is expected to grow at 8-10% CAGR, reaching over $2.2 billion in revenue by 2025.
- Current list prices hover around $33,000 annually, with modest declines projected over the next five years due to increased biosimilar competition and pricing pressures.
- Market penetration is high, but growth may slow as new competitors emerge and policy measures tighten.
- The biosimilar landscape remains a key factor influencing long-term pricing and market share.
References
- MarketResearch.com, "Global Asthma Drugs Market Analysis," 2022.
- IQVIA, "U.S. Biologics in Respiratory Diseases," 2022.
- U.S. Federal Register, "Payer Coverage of Biologics," 2023.
- Pharma Intelligence, "Biologics Pricing Trends," 2022.
FAQs
Q1: What are the main competitors to NDC 72603-0322?
A1: Mepolizumab (Nucala), Reslizumab (Cinqair), and Dupilumab (Dupixent).
Q2: How is the drug's market share expected to change by 2028?
A2: Market share is likely to stabilize but face pressure from biosimilars and new entrants, potentially reducing its dominance.
Q3: What factors could cause significant price declines?
A3: Patent expirations, biosimilar approvals, increased price regulation, and payer negotiations.
Q4: Are there any off-label uses that could expand the market?
A4: Potential off-label applications include COPD and other eosinophilic conditions, but regulatory approval is pending.
Q5: How might reimbursement policies impact future revenue?
A5: Policies favoring cost containment could lead to reduced prices and reimbursement levels, impacting revenue projections.
Note: Data reflects projections and estimates based on current market trends as of 2023 and may evolve with regulatory and competitive developments.
